PharmaShots | Incisive News in 3 Shots

Subscribe Now

ipilimumab

Innovent and HUTCHMED Report P-II/III (FRUSICA-2) Trial Data of Sintilimab + Fruquintinib for Metastatic Renal Cell Carcinoma (RCC)

Innovent and HUTCHMED Report P-II/III (FRUSICA-2) Trial Data of Sintilimab + Fruquintinib for Metastatic Renal Cell Carcinoma (RCC...

March 19, 2025

Innovent Reports the NMPA’s NDA Acceptance & Priority Review of Neoadjuvant Ipilimumab + Sintilimab for Colon Cancer

Innovent Reports the NMPA’s NDA Acceptance & Priority Review of Neoadjuvant Ipilimumab + Sintilimab for Colon Cancer

February 24, 2025

New Drug Designations - October 2023

New Drug Designations - October 2023

November 21, 2023

Shanghai Henlius Biotech Receives the NMPA’s IND Approval of HLX13 (biosimilar, ipilimumab) for the Treatment of Hepatocellular Carcinoma

Shanghai Henlius Biotech Receives the NMPA’s IND Approval of HLX13 (biosimilar, ipilimumab) for the Treatment of Hepatocellular Ca...

June 26, 2023

Ono Pharmaceutical’s Opdivo (nivolumab) + Yervoy (ipilimumab) Receives the MFDS Approval as 1L Treatment of Esophageal Squamous Cell Carcinoma in South Korea

Ono Pharmaceutical’s Opdivo (nivolumab) + Yervoy (ipilimumab) Receives the MFDS Approval as 1L Treatment of Esophageal Squamous Ce...

March 23, 2023

Top Performing Drug of 2021 – Opdivo (December Edition)

Top Performing Drug of 2021 – Opdivo (December Edition)

December 22, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us